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OBJECTIVES: To compare the yearly expenditure per capita of
the following high-cost health care programs available in the
Brazilian public health care system: severe Rheumatoid Arthritis,
renal replacement therapy, Hepatitis, Aids and Oncology.
METHODS: A survey in the ofﬁcial health care database (http://
www.datasus.gov.br) was conducted to gather: 1) the amount of
resources spent (annual budget), and 2) the number of patients
treated in each program in 2007. Those data were then cross-
checked with some public information found in the Ministry of
Health website (www.saude.gov.br) and from medical societies.
For the Aids program an article published by Grangeiro et al. in
2006 was used since it resulted from an extensive research and
both data on drugs expenditure and the number of patients in
2007 were not available in the ofﬁcial health care database.
Based on that article the annual budget and number of patients
for the Aids program were updated by the ofﬁcial inﬂation rate
and the ofﬁcial incidence rate, respectively. Then the yearly
expenditure per capita for each program was calculated. A limi-
tation of this study is the expenditure per capita calculated for
the Oncology program. Since there is no ofﬁcial data regarding
the prevalence of oncological diseases in Brazil only new cases
(incidence) were considered for the calculation, so the ﬁnal
expenditure per capita is likely to be lower than the one calcu-
lated in this study. RESULTS: Severe Rheumatoid Arthritis:
R$82,060,720 for 2,098 patients = R$39,120 per patient per
year (the highest expenditure per capita); renal replacement
therapy: R$1,397,958.956 for 73,605 patients = R$18,993
per patient per year; Hepatitis: R$295,428,000 for 44,598
patients = 6,624 per patient per year; Aids program:
R$1,062,316,834 for 168,417 patients = R$6,308 per patient
per year; Oncology: R$1,026,017,544 for 472,000 patients =
R$2,174 per patient per year (the lowest yearly expenditure per
capita). CONCLUSIONS: Findings indicate signiﬁcant differ-
ences in the yearly expenditure per capita for each program.
Further studies are recommended to extend this analysis and to
explore the reasons for those differences.
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OBJECTIVES: To estimate the daily costs of intensive care unit
(ICU)-stay with a focus on mechanical ventilation (MV) in three
European countries. METHODS: This retrospective cost study
was conducted in one German, one Italian and three Dutch adult
medical-surgery ICUs, from a hospital perspective. A microcost-
ing approach was applied, implying that all relevant cost com-
ponents were identiﬁed and valued at a detailed level. Direct cost
included medical imaging services, laboratory procedures, drugs,
ﬂuids, disposables, inpatient stay, and labour. Indirect costs
consist of overheads and capital. Resource use was primarily
derived from hospital administrative databases. Unit costs were
acquired from ﬁnancial hospital databases and hospital phar-
macy databases. Overheads and capital costs were appointed to
patients using a marginal mark-up percentage. The reference year
was 2006. RESULTS: Total daily costs amounted to €1225 in
Germany, €1472 in Italy and €1911 in The Netherlands, with
labour and overheads as the most important cost drivers. Direct
daily costs were €1040 in Germany, €1333 in Italy and €1243 in
The Netherlands. Hence, the cost differences between the coun-
tries were mainly driven by diverging indirect costs. Mechanical
ventilation in critically ill patients was associated with a 21% to
29% cost increase. CONCLUSIONS: The direct but not the
indirect costs of intensive care are in the same range in Germany,
Italy and The Netherlands. Mechanical ventilation leads to sub-
stantial higher ICU costs.
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OBJECTIVES: To determine the effects of different drivers for
changes of the overall expenses for pharmaceuticals in Germa-
ny’s social health insurance (SHI) from 2006 (26.4 bn Euro) to
2007 (28.0 bn Euro). To determine the role of shifts towards the
prescription of more costly follow-on drugs. METHODS: Analy-
sis was based on sales data on 90,027 different drug preparations
having been prescribed in 2006 and 2007. An overall of 636 m
(2006) resp. 650 m (2007) prescriptions represented 97% of all
drug expenses of the SHI. By calculating index numbers we
estimated the inﬂuences of quantities, prices, and eight structural
components, amid others shifts between classes of drugs as well
as shifts between compounds within classes of drugs. The latter
indicates shifts towards more costly follow-on drugs. Analyses
have been carried out for 95 different indication groups.
RESULTS: Sales increased for 1.6 bn Euro and the prescribed
quantities of drugs for 1.9 bn from 33.2 bn to 35.1 bn DDD. The
higher quantity of prescribed DDD enhanced sales by 2.2 bn
Euro. Reduced prices resulted in savings of 0.2 bn Euro. A higher
cost efﬁciency of prescribing was also achieved by an increased
prescription of generic drugs, larger packages and drugs of higher
dosage strength summing up to savings of about 0.5 bn Euro. In
the two drug groups with the highest quantity of prescribed DDD
(ACE inhibitors: 3.2 bn DDD; statins: 2.1 bn DDD) the propor-
tion of Ramipril and Simvastatin increased from 49 to 57% and
from 79 to 85%, respectively. CONCLUSIONS: The most
important cost driver was the increase of the number of pre-
scribed DDD reﬂecting unserved needs in frequent indications in
former years. Shifts to more costly follow-on drugs had no
impact on the overall costs.
PHP31
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OBJECTIVES: To estimate the budget impact of the reimburse-
ment of a follow-up on patent medicine prior to the patent
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